Table 3

IPA: canonical pathways enriched for biomarkers of incident DSPN

1Granulocyte adhesion and diapedesis1.45E-07CXCL10, CCL20, CCL3, CXCL9, CCL19, CCL7, TNFRSF11B
2Altered T cell and B cell signaling in rheumatoid arthritis3.02E-06SLAMF1, CD40, IL12B, CSF1, LTA
3Agranulocyte adhesion and diapedesis3.02E-06CXCL10, CCL20, CCL3, CXCL9, CCL19, CCL7
4Pathogenesis of multiple sclerosis3.24E-06CXCL10, CCL3, CXCL9
5T helper cell differentiation3.47E-05CD40, IL12B, IL10RB, TNFRSF11B
6Hepatic fibrosis/hepatic stellate cell activation3.98E-05CD40, CSF1, HGF, CXCL9, TNFRSF11B
7Cross talk between dendritic cells and natural killer cells5.50E-05IL15RA, CD40, IL12B, LTA
8Communication between innate and adaptive immune cells5.89E-05CXCL10, CD40, IL12B, CCL3
9Role of hypercytokinemia/hyperchemokinemia in the pathogenesis of influenza2.00E-04CXCL10, IL12B, CCL3
10Th1 pathway2.00E-04CD40, IL12B, LTA, IL10RB
11Hepatic cholestasis3.55E-04IL12B, LTA, FGF19, TNFRSF11B
12Th1 and Th2 activation pathway5.62E-04CD40, IL12B, LTA, IL10RB
13Dendritic cell maturation6.03E-04CD40, IL12B, LTA, TNFRSF11B
14TREM1 signaling7.08E-04CD40, CCL3, CCL7
  • The table shows all canonical pathways (PB-H <10−3) based on significant associations between biomarkers of inflammation and incident DSPN in the fully adjusted model (see also Table 1) and the biomarkers belonging to the respective pathway.